SCHEMBL6495287

SCHEMBL6495287

CCCCCOc1ccc(Cn2c(C)nc3ccc(OCCC(C)(C)C(=O)O)cc32)c(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.48
ALOX5AP P20292 18/20 0.43
PPARD Q03181 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6497616 0.91 PPARG (0.47) PPARGALOX5AP
SCHEMBL6498420 0.90 ALOX5AP (0.49) PPARGALOX5AP
SCHEMBL6490405 0.90 PPARG (0.48) PPARGALOX5APPPARD
SCHEMBL6499263 0.89 ALOX5AP (0.41) PPARGALOX5APPPARD
SCHEMBL6487612 0.87 PPARG (0.51) PPARGALOX5AP
SCHEMBL6492145 0.87 PPARG (0.51) PPARGALOX5AP
SCHEMBL6498744 0.87 PPARG (0.51) PPARGALOX5AP
SCHEMBL6491422 0.87 PPARG (0.51) PPARGALOX5AP
SCHEMBL6500098 0.86 PPARG (0.50) PPARGALOX5AP
SCHEMBL6301607 0.86 PPARG (0.58) PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed
WO-2004108686-A2 BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD PPARG 233/4885ALOX5AP 4663/4885PPARD 290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.